Benefits and risks of treatment with ipilimumab after complete resection of Stage III melanoma

Benefits and risks of treatment with ipilimumab after complete resection of Stage III melanoma

VJOncology

2 years
269 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dirk Schadendorf, MD, PhD, from the University Hospital Essen, Essen, Germany, discusses the risks and benefits of adjuvant ipilimumab treatment after complete resection of Stage III melanoma based on the results of a recent Phase III trial (EORTC 18071, NCT00636168) at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Prof. Schadendorf describes that patients receiving adjuvant ipilimumab treatment following surgical resection of Stage III melanoma, who are at risk of relapse, have an 11% increase in overall survival (OS) after 5 years. However, 50% of Stage III melanoma patients are surviving to 5 years without adjuvant treatment after resection, and maintenance therapy at a dose of 10 mg/kg for up to 3 years, as was used in this trial, is accompanied by high toxicity and high incidence of side effects including severe colitis, and is also associated with high cost, which leads to debate about whether these patients should be exposed to this toxic treatment. Prof. Schadendorf argues that once a 5-year survival is achieved, there is a high chance of long-term survival or cure of melanoma, but points out the advantages of identifying patients who will benefit from adjuvant ipilimumab treatment after Stage III melanoma resection, perhaps through the development of biomarkers.
Up Next Autoplay
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
2 Views
Cancer-News 9 hours
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 10 hours
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
2 Views
Cancer-News 10 hours
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 3 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 3 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 3 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
2 Views
Cancer-News 3 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 5 days